These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31500643)

  • 21. Meta-analysis of genotype-phenotype analysis of OPA1 mutations in autosomal dominant optic atrophy.
    Ham M; Han J; Osann K; Smith M; Kimonis V
    Mitochondrion; 2019 May; 46():262-269. PubMed ID: 30165240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.
    Amati-Bonneau P; Valentino ML; Reynier P; Gallardo ME; Bornstein B; Boissière A; Campos Y; Rivera H; de la Aleja JG; Carroccia R; Iommarini L; Labauge P; Figarella-Branger D; Marcorelles P; Furby A; Beauvais K; Letournel F; Liguori R; La Morgia C; Montagna P; Liguori M; Zanna C; Rugolo M; Cossarizza A; Wissinger B; Verny C; Schwarzenbacher R; Martín MA; Arenas J; Ayuso C; Garesse R; Lenaers G; Bonneau D; Carelli V
    Brain; 2008 Feb; 131(Pt 2):338-51. PubMed ID: 18158317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathogenicity evaluation and the genotype-phenotype analysis of OPA1 variants.
    Xu X; Wang P; Jia X; Sun W; Li S; Xiao X; Hejtmancik JF; Zhang Q
    Mol Genet Genomics; 2021 Jul; 296(4):845-862. PubMed ID: 33884488
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Heterozygous deletion of the OPA1 gene in patients with dominant optic atrophy.
    Hayashi T; Sasano H; Katagiri S; Tsunoda K; Kameya S; Nakazawa M; Iwata T; Tsuneoka H
    Jpn J Ophthalmol; 2017 Sep; 61(5):395-401. PubMed ID: 28668999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion.
    Zanna C; Ghelli A; Porcelli AM; Karbowski M; Youle RJ; Schimpf S; Wissinger B; Pinti M; Cossarizza A; Vidoni S; Valentino ML; Rugolo M; Carelli V
    Brain; 2008 Feb; 131(Pt 2):352-67. PubMed ID: 18222991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mutation spectrum of the OPA1 gene in a large cohort of patients with suspected dominant optic atrophy: Identification and classification of 48 novel variants.
    Weisschuh N; Schimpf-Linzenbold S; Mazzola P; Kieninger S; Xiao T; Kellner U; Neuhann T; Kelbsch C; Tonagel F; Wilhelm H; Kohl S; Wissinger B
    PLoS One; 2021; 16(7):e0253987. PubMed ID: 34242285
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Distributed abnormalities of brain white matter architecture in patients with dominant optic atrophy and OPA1 mutations.
    Rocca MA; Bianchi-Marzoli S; Messina R; Cascavilla ML; Zeviani M; Lamperti C; Milesi J; Carta A; Cammarata G; Leocani L; Lamantea E; Bandello F; Comi G; Falini A; Filippi M
    J Neurol; 2015 May; 262(5):1216-27. PubMed ID: 25794858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fourteen novel OPA1 mutations in autosomal dominant optic atrophy including two de novo mutations in sporadic optic atrophy.
    Baris O; Delettre C; Amati-Bonneau P; Surget MO; Charlin JF; Catier A; Derieux L; Guyomard JL; Dollfus H; Jonveaux P; Ayuso C; Maumenee I; Lorenz B; Mohammed S; Tourmen Y; Bonneau D; Malthièry Y; Hamel C; Reynier P
    Hum Mutat; 2003 Jun; 21(6):656. PubMed ID: 14961560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteristics of autosomal dominant WFS1-associated optic neuropathy and its comparability to OPA1-associated autosomal dominant optic atrophy.
    de Muijnck C; Haer-Wigman L; van Everdingen JAM; Lushchyk T; Heutinck PAT; van Dooren MF; Kievit AJA; Verhoeven VJM; Simon MEH; Wasmann RA; Notting IC; De Baere E; Walraedt S; De Zaeytijd J; Van den Broeck F; Leroy BP; Boon CJF; van Genderen MM
    Sci Rep; 2024 Oct; 14(1):22956. PubMed ID: 39363032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Plasma Metabolomic Signature Involving Purine Metabolism in Human Optic Atrophy 1 (OPA1)-Related Disorders.
    Bocca C; Kouassi Nzoughet J; Leruez S; Amati-Bonneau P; Ferré M; Kane MS; Veyrat-Durebex C; Chao de la Barca JM; Chevrollier A; Homedan C; Verny C; Miléa D; Procaccio V; Simard G; Bonneau D; Lenaers G; Reynier P
    Invest Ophthalmol Vis Sci; 2018 Jan; 59(1):185-195. PubMed ID: 29340645
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dominant optic atrophy: correlation between clinical and molecular genetic studies.
    Puomila A; Huoponen K; Mäntyjärvi M; Hämäläinen P; Paananen R; Sankila EM; Savontaus ML; Somer M; Nikoskelainen E
    Acta Ophthalmol Scand; 2005 Jun; 83(3):337-46. PubMed ID: 15948788
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Autosomal dominant optic atrophy caused by six novel pathogenic OPA1 variants and genotype-phenotype correlation analysis.
    Han J; Li Y; You Y; Fan K; Lei B
    BMC Ophthalmol; 2022 Jul; 22(1):322. PubMed ID: 35883160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recessive optic atrophy, sensorimotor neuropathy and cataract associated with novel compound heterozygous mutations in OPA1.
    Lee J; Jung SC; Hong YB; Yoo JH; Koo H; Lee JH; Hong HD; Kim SB; Chung KW; Choi BO
    Mol Med Rep; 2016 Jul; 14(1):33-40. PubMed ID: 27150940
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deciphering OPA1 mutations pathogenicity by combined analysis of human, mouse and yeast cell models.
    Del Dotto V; Fogazza M; Musiani F; Maresca A; Aleo SJ; Caporali L; La Morgia C; Nolli C; Lodi T; Goffrini P; Chan D; Carelli V; Rugolo M; Baruffini E; Zanna C
    Biochim Biophys Acta Mol Basis Dis; 2018 Oct; 1864(10):3496-3514. PubMed ID: 30293569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validation of a MGM1/OPA1 chimeric gene for functional analysis in yeast of mutations associated with dominant optic atrophy.
    Nolli C; Goffrini P; Lazzaretti M; Zanna C; Vitale R; Lodi T; Baruffini E
    Mitochondrion; 2015 Nov; 25():38-48. PubMed ID: 26455272
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutation spectrum and splicing variants in the OPA1 gene.
    Delettre C; Griffoin JM; Kaplan J; Dollfus H; Lorenz B; Faivre L; Lenaers G; Belenguer P; Hamel CP
    Hum Genet; 2001 Dec; 109(6):584-91. PubMed ID: 11810270
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genotype-phenotype and OCT correlations in Autosomal Dominant Optic Atrophy related to OPA1 gene mutations: Report of 13 Italian families.
    Pretegiani E; Rosini F; Rufa A; Gallus GN; Cardaioli E; Da Pozzo P; Bianchi S; Serchi V; Collura M; Franceschini R; Bianchi Marzoli S; Dotti MT; Federico A
    J Neurol Sci; 2017 Nov; 382():29-35. PubMed ID: 29111013
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular Impairment Mechanisms of Novel OPA1 Mutations Predicted by Molecular Modeling in Patients With Autosomal Dominant Optic Atrophy and Auditory Neuropathy Spectrum Disorder.
    Namba K; Mutai H; Takiguchi Y; Yagi H; Okuyama T; Oba S; Yamagishi R; Kaneko H; Shintani T; Kaga K; Matsunaga T
    Otol Neurotol; 2016 Apr; 37(4):394-402. PubMed ID: 26905822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intrafamilial "DOA-plus" phenotype variability related to different OMI/HTRA2 expression.
    Napolitano F; Terracciano C; Bruno G; Nesti C; Barillari MR; Barillari U; Santorelli FM; Melone MAB; Esposito T; Sampaolo S
    Am J Med Genet A; 2020 Jan; 182(1):176-182. PubMed ID: 31609081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OPA1 gene therapy prevents retinal ganglion cell loss in a Dominant Optic Atrophy mouse model.
    Sarzi E; Seveno M; Piro-Mégy C; Elzière L; Quilès M; Péquignot M; Müller A; Hamel CP; Lenaers G; Delettre C
    Sci Rep; 2018 Feb; 8(1):2468. PubMed ID: 29410463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.